Q1 FY27 earnings call transcript filed; revenue up 25% year-on-year

Mgmt Guided Margin ImprovementOrder Pipeline DisclosedInvestor Communications View source PDF Explain this filing

JUBLINGREA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.1%1-day move

₹745.00

prior close

₹747.40

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.4-0.8-0.7-0.9-1.1-2.4-1.3+1.7+0.7+1.4-2.1-8.2-11.3—

Up moveDown movePending

AI summary

Jubilant Ingrevia filed Q1 FY27 earnings call transcript. Revenue grew 25% year-on-year to INR 1,300 crore, a 15-quarter high. EBITDA rose 36% to INR 209 crore; PAT up 41% to INR 106 crore. Specialty Chemicals margins hit 26%; Nutrition revenue up 36% with 3-year high segment EBITDA. CDMO pipeline has 100-plus molecules worth over INR 3,500 crore in peak potential, 25 confirmed. Full-year EBITDA guidance of INR 750-800 crore maintained with sequential growth expected.

Likely market impact

Strong Q1 results support maintained INR 750-800 crore full-year EBITDA guidance; sequential growth expected but large CDMO contract volumes remain uncertain.